Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings to benefit from federal government changes

The significant regulatory change will authorise controlled importation of medical cannabis.
AusCann Group Holdings to benefit from federal government changes
The regulatory change has seen the stock jump up 45% to $0.29

AusCann Group Holdings (ASX:AC8) welcomes the federal government’s move to facilitate faster access to medical cannabis for patients.

The significant regulatory change will authorise controlled importation of medical cannabis by approved suppliers from international sources.

This will allow AusCann to import product ahead of time to meet demand from authorised prescribers and be in a position to more quickly provide patient access.

This will significantly accelerate AusCann’s timeline in being able to supply Australian patients.

Elaine Darby, managing director, commented: “We welcome the decision by the government to accelerate patient access to medicinal cannabis products.

“It is encouraging that they have been listening to patients and doctors and acting on their concerns.”


Background

Medical cannabis company, AusCann, commenced trading on the ASX earlier this month after completing a successful reverse takeover of TW Holdings.

The company raised the maximum $5 million under its prospectus offering by issuing 25 million shares priced at $0.20.

AusCann intends to establish a growing facility in Australia to eventually supply Australian patients with Australian grown and manufactured medicines.

However, until domestic approvals are received, AusCann’s medicinal products will be imported from its partner Canopy Growth Corporation that is globally recognised as one of the leaders in medicinal cannabis.

AusCann is also on track to harvest its first medicinal cannabis crop in Chile in April 2017 through its 50:50 partnership with Fundacion Daya.


Analysis

This regulatory change will drive AusCann’s strategy to deliver high quality, cost effective medicinal cannabis treatments to Australian patients.

As more doctors seek to become authorised prescribers of the medication, AusCann is well placed among the medical community to be the supplier of choice for doctors and patients.

Moreover, this move by the government clearly signals its commitment to bring this medication to patients, Australia-wide.

The regulatory change has seen the stock jump up 45% to $0.29.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Cannabis leaf
Sat
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
Laboratory testing
October 10 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use